Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study

2010 ◽  
Vol 84 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Massimo Porena ◽  
Michele Del Zingaro ◽  
Massimo Lazzeri ◽  
Luigi Mearini ◽  
Antonella Giannantoni ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Prospective Study ◽  
Superficial Bladder Cancer ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin

The Possible Influence of Antibiotics on Results of Bacillus Calmette-Guérin Intravesical Therapy for Superficial Bladder Cancer

1991 ◽  
Vol 146 (2 Part 1) ◽  
pp. 444-446 ◽  
Author(s):  
Ad P.M. Van Der Meijden ◽  
Bert Van Klingeren ◽  
Peter A. Steerenberg ◽  
Liesbeth C. De Boer ◽  
Wim H. De Jong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin

Bacillus Calmette-Guerin Therapy for High Risk Stage T1 Superficial Bladder Cancer

1992 ◽  
Vol 147 (2) ◽  
pp. 376-379 ◽  
Author(s):  
Gregg R. Eure ◽  
Maria R. Cundiff ◽  
Paul F. Schellhammer
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Stage T1

Results after two years of follow up after intravesical thermochemotherapy with heated mitomycin 40 in patients with high-risk superficial bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 512-512
Author(s):  
Thomas Alexander Voegeli ◽  
Eric Frank ◽  
Christian Bach ◽  
Catejan Nzeh
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Alternative Treatment ◽  
Superficial Bladder Cancer ◽  
Treatment Options ◽  
High Rate ◽  
Intravesical Therapy ◽  
Bladder Irrigation ◽  
Metastatic Prostate Carcinoma

512 Background: Standard management of high risk TCC is either BCG or radical cystectomy, alternative treatment options are limited. It is known that the anti-tumor effect of heated mitomycin is 10 fold higher than at room temperature, which is the standard of intravesical therapy. We herein report the first 2 year follow up (FU) after intravesical therapy with heated mitomycin in a cohort of patients with high risk superficial bladder cancer (TCC). Methods: Treatment was performed for 1 hour with machine bladder irrigation (COMBAT) which maintaines temperature of mitomycin (40 mg) exactly at 43 C. Patients underwent therapy with a 6 week course of weekly treatment and were than followed by cystoscopy every 3 month and if necessary biopsy. Results: We identified 62 patients out of a total group of 108 patients who met the inclusion criteria for high risk TCC according to the EAU Guidelines and who got the complete 6 courses of treatment. 2 were lost of follow up, 1 died due to cardiac problems and 1 from metastatic prostate carcinoma. The remaining 58 patients had a mean FU of 26 month (16-54 m) and included 20 non-responders to BCG. 48/58 patients had CIS or pT1 Tumors or both, 10 patients had pTa+CIS. There were 5 recurrences, all superficial stage pTa, one in the rigth ureter, all could be managed without cystectomy. 8 patients had progressive or recurrent CIS/pT1 or were progressive to pT2 after therapy and underwent cystectomy. Conclusions: In this high risk cohort of 58 patients with a high rate of BCG non-responders only 8 patients had to undergo cystectomy during a 2 year follow up. Intravesical therapy with heated mitomycin is safe and well tolerated and may be an additional alternative treatment before cystectomy is performed in high risk patients with high risk TCC or BCG non responders.

Sign in / Sign up

Export Citation Format

Share Document